Synthesis, molecular modeling and NAD(P)H:quinone oxidoreductase 1 inducer activity of novel 2-phenylquinazolin-4-amine derivatives by Ghorab, Mostafa M. et al.
                                                              
University of Dundee
Synthesis, molecular modeling and NAD(P)H
Ghorab, Mostafa M.; Alsaid, Mansour S.; Higgins, Maureen; Dinkova-Kostova, Albena;
Shahat, Abdelaaty A.; Elghazawy, Nehal H.; Arafa, Reem K.
Published in:
Journal of Enzyme Inhibition and Medicinal Chemistry
DOI:
10.3109/14756366.2016.1158714
Publication date:
2016
Document Version
Accepted author manuscript
Link to publication in Discovery Research Portal
Citation for published version (APA):
Ghorab, M. M., Alsaid, M. S., Higgins, M., Dinkova-Kostova, A. T., Shahat, A. A., Elghazawy, N. H., & Arafa, R.
K. (2016). Synthesis, molecular modeling and NAD(P)H: quinone oxidoreductase 1 inducer activity of novel 2-
phenylquinazolin-4-amine derivatives. Journal of Enzyme Inhibition and Medicinal Chemistry, 31(6), 1612-1618.
DOI: 10.3109/14756366.2016.1158714
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 28. Apr. 2017
	
	
1	
	
Synthesis,	molecular	modeling	and	NAD(P)H:quinone	oxidoreductase	1	
inducer	activity	of	novel	2-phenylquinazolin-4-amine	derivatives	
	
Mostafa	M.	Ghorab1,2*,	Mansour	S.	Alsaid1,	Maureen	Higgins3,	Albena	T.	Dinkova-
Kostova3,4,		Abdelaaty	A.	Shahat1,5,	Nehal	H.	Elghazawy6,	Reem	K.	Arafa6,7	
	
1Department	of		Pharmacognosy,	College	of	Pharmacy,	King	Saud	University,	P.O.	Box	2457,	
Riyadh	11451,	Kingdom	of	Saudi	Arabia;	2Department	of	Drug	Radiation	Research,	National	
Center	for	Radiation	Research	&	Technology,	Atomic	Energy	Authority,	P.O.Box	29	Nacer	City,	
Cairo,	Egypt;	3Jacqui	Wood	Cancer	Centre,	Division	of	Cancer	Research,	Medical	Research	
Institute,	University	of	Dundee,	Dundee	DD1	9SY,	United	Kingdom;	4Departments	of	Medicine	
and	Pharmacology	and	Molecular	Sciences,	Johns	Hopkins	University	School	of	Medicine,	
Baltimore,	MD	21205,	USA;	5Phytochemistry	Department	National	Research	Center;	6	Zewail	City	
of	Science	and	Technology,	12588,	Cairo,	Egypt;		7Department	of	Pharmaceutical	Chemistry,	
Faculty	of	Pharmacy,	Cairo	University,	11562,	Cairo,	Egypt.	
	
Abstract	
Reactive	oxygen	species	(ROS)	play	an	integral	role	in	the	pathogenesis	of	most	diseases.	
This	 work	 presents	 the	 design	 and	 synthesis	 of	 novel	 2-phenylquinazolin-4-amine	
derivatives	 (2-12)	 and	 evaluation	 of	 their	 NAD(P)H:quinone	 oxidoreducase	 1	 (NQO1)	
inducer	activity	in	murine	cells.	Also,	molecular	docking	of	all	the	new	compounds	was	
performed	 to	 assess	 their	 ability	 to	 inhibit	 Keap1-Nrf2	 protein-protein	 interaction	
through	 occupying	 the	 Keap1	 Nrf2-binding	 domain	 which	 biologically	 leads	 to	 a	
consequent	Nrf2	accumulation	and	enhanced	gene	expression	of	NQO1.	Docking	results	
showed	that	all	compounds	have	the	ability	to	interact	with	Keap1;	however	compound	
7,	 the	most	active	compound	 in	 this	 study,	 showed	more	 interactions	with	key	amino	
acids.		
	
	
Keywords:	2-phenylquinazolin-4-amine	derivatives,	molecular	modeling,	Keap1/Nrf2,	
cytoprotection,	NQO1	induction.		
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Introduction	
Excessive	unbalanced	production	of	 reactive	oxygen	species	 (ROS),	namely	 superoxide	
anion	 radical	 (O2-.),	 singlet	oxygen	 (1O2),	hydroxyl	 radical	 (.OH)	and	hydrogen	peroxide	
(H2O2),	 has	 been	well	 established	 to	 be	 associated	with	many	 pathological	 conditions	
including	 atherosclerosis,	 stroke,	 diabetes,	 Alzheimer’s	 disease,	 cancer	 and	
inflammation	1.	In	a	counter	action	and	to	maintain	homeostasis,	living	cells	combat	the	
deleterious	effects	of	ROS	by	an	arsenal	of	biochemical	antioxidants.2,3.	Under	oxidative	
stress	conditions;	where	the	balance	between	ROS	and	biochemical	antioxidants	is	lost	
due	to	over	production	of	the	former	or	under	availability	of	the	latter;	ROS	can	attack	
and	 damage	 cellular	membrane	 lipids,	 DNA	 nucleotides4,	 proteins’	 sulphydryl	 groups5	
and	ribonucleoproteins6.	Among	the	most	important	antioxidant	mechanisms	activated	
under	conditions	of	oxidative	stress	 is	the	Kelch-like	ECH-associated	protein	1	(Keap1)-
nuclear	factor	erythroid	2-related	factor	2	(Nrf2)-antioxidant	response	elements	(AREs)	
pathway7.	 This	 pathway	 is	 associated	 with	 the	 expression	 of	 more	 than	 100	
cytoprotective	 genes	 and	 their	 respective	 enzymes,	 one	 of	which	 is	NAD(P)H:quinone	
oxidoreductase	 1	 (NQO1,	 EC	 1.6.99.2).	 Under	 homeostatic	 conditions,	 Nrf2	 is	
continuously	 targeted	 for	 ubiquitination	 and	 proteasomal	 degradation	 by	 Keap1.	
However,	upon	increased	oxidative	load,	reactive	cysteine	residues	within	Keap1	serve	
as	 sensors	 for	 oxidants,	 leading	 to	 loss	 of	 its	 ability	 to	 target	 Nrf2	 for	 degradation,	
subsequent	 accumulation	 of	 the	 transcription	 factor,	 activation	 of	 the	 pathway	 and	
increased	transcription	of	cytoprotective	antoxidant	proteins8-10.	
Medicinal	chemists	view	the	Keap1-Nrf2	protein-protein	interaction	as	a	critical	point	of	
the	pathway	that	can	be	targeted	for	 intervention	and	for	potential	management	of	a	
variety	 of	 oxidative	 stress-related	 ailments	 like	 cancer,	 Parkinson’s,	 Alzheimer’s	 and	
diabetes11-14.	 Design	 of	 non-covalent	 small	 molecule	 modulators	 of	 the	 Keap-Nrf2	
interaction	 has	 been	 widely	 explored15,16.	 Quinazoline-based	 nitrogenous	 heteroaryls	
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are	an	excellent	reservoir	of	bioactive	substances	where	a	number	of	biological	activities	
have	been	associated	with	antioxidant	activity17-19.		
In	 continuation	 of	 our	 quest	 for	 new	 cytoprotective	 agents20,21,	we	 herein	 report	 the	
synthesis,	 NQO1	 inducer	 activity	 and	 Keap1	 inhibitory	 in	 silico	 screening	 results	 for	 a	
novel	class	of	N-aryl	substituted	4-amino-2-phenylquinazolines.		
	
Materials	and	Methods		
Chemistry	
Melting	 points	 (uncorrected)	 were	 determined	 in	 open	 capillary	 on	 a	 Gallen	 Kamp	
melting	point	apparatus	(Sanyo	Gallen	Kamp,	UK).	Precoated	silica	gel	plates	(Kieselgel	
0.25	 mm,	 60	 F254,	 Merck,	 Germany)	 were	 used	 for	 thin	 layer	 chromatography.	 A	
developing	solvent	system	of	chloroform/methanol	(8:2)	was	used	and	the	spots	were	
detected	 by	 ultraviolet	 light.	 IR	 spectra	 (KBr	 disc)	 were	 recorded	 using	 an	 FT-IR	
spectrophotometer	 (Perkin	 Elmer,	 USA).	 NMR	 spectra	 were	 scanned	 on	 a	 NMR	
spectrophotometer	 (Bruker	 AXS	 Inc.,	 Switzerland),	 operating	 at	 500	 MHz	 for	 1H	 and	
125.76	MHz	for	13C.	Chemical	shifts	are	expressed	in	δ-values	(ppm)	relative	to	TMS	as	
an	 internal	 standard,	using	DMSO-d6	 as	a	 solvent.	Elemental	analyses	were	done	on	a	
model	2400	CHNSO	analyzer	(Perkin	Elmer,	USA).	All	the	values	were	within	±	0.4	%	of	
the	 theoretical	 values.	 All	 reagents	 used	 were	 of	 AR	 grades.	 The	 starting	material	 4-
chloro-2-phenylquinazoline	(1)	was	purchased	from	sigma	(USA)	and	was	directly	used	
for	the	preparation	of	target	compounds.	
	
Synthesis	of	2-Phenyl-4-substituted	quinazoline	derivatives	2-12.	
General	procedure	
A	mixture	of	 	2-phenyl	4-chloroquinazoline	1	 (2.40	gm,	0.01	mol)	and	different	amines	
(0.01	 mol)	 in	 dimethylformamide	 (10	 mL)	 containing	 a	 catalytic	 amount	 of	
trimethylamine	 (3	 drops)	 was	 refluxed	 for	 24	 h.	 then	 left	 to	 cool.	 The	 solid	 product	
formed	was	collected	by	filtration	and	recrystallized	from	acetic	acid	to	give	the	desired	
quinazoline	derivatives	2-12,	respectively.	
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N-(2,3-Dihydro-1H-inden-5-yl)-2-phenylquinazolin-4-amine	(2).		
White	solid;	yield,	76%;	m.p.	118-9	oC.	IR	(KBr,	cm-1):	3401	(NH),	3080	(CH	arom.),	2976,	
2778	(CH	aliph.),	1631	(C=N).	1H-NMR	(DMSO-d6):	ppm	1.9-2.8	[m.	6H,	3CH2,	Cyclo],	7.1-
9.0	[m,	12H,	Ar-H],	11.8	[s,	1H,	NH,	exchangeable	with	D2O].	13C-NMR	(DMSO-d6):	ppm	
25.6,	32.9	 (2),	113.1,	121.6,	123.0,	124.4,	125.4,	128.3	 (2),	129.3,	129.4,	129.7,	129.8,	
133.7	(2),	135.3,	136.1,	142.3,	144.5	(2),	157.3,	159.1.	MS	m/z	(%):	337	(M+)	(16.73),	219	
(100).	Anal.	 Calcd.	 For	C23H19N3	 (337):	C,	 81.87;	H,	 5.68;	N,	12.45.	 Found:	C,	 81.53;	H,	
5.94;	N,	12.14.	
	
N-(Benzo[d][1,3]dioxol-5-yl)-2-phenylquinazolin-4-amine	(3).		
Pale	yellow	solid;	yield,	89%;	m.p.	107-8	oC.	IR	(KBr,	cm-1):	3441	(NH),	3081	(CH	arom.),	
2984,	2874	(CH	aliph.),	1617	(C=N).	1H-NMR	(DMSO-d6):	ppm	6.0	[s,	2H,	O-CH2-O],	7.0-
8.5	 [m,	12H,	Ar-H],	9.7	 [s,	1H,	NH,	exchangeable	with	D2O].	 13C-NMR	 (DMSO-d6):	ppm	
101.4,	104.8,	108.6,	114.4,	115.8,	123.3,	126.2	(2),	128.3,	128.5,	128.8	(2),	130.6,	133.5,	
133.9,	 138.8	 (2),	 147.4,	 150.8,	 159.6,	 162.7.	MS	m/z	 (%):	 	 341	 (M+)	 (3.65),	 294	 (100).	
Anal.	Calcd.	For	C21H15N3O2	(341):	C,	73.89;	H,	4.43;	N,	12.31.	Found:	C,	74.11;	H,	4.75;	N,	
12.65.	
	
N-(Benzo[d][1,3]dioxol-5-ylmethyl)-2-phenylquinazolin-4-amine	(4).		
Tan	white	solid;	yield,	80%;	m.p.	180-1	oC.	 IR	 (KBr,	cm-1):	3238	(NH),	3069	(CH	arom.),	
2944,	2791	(CH	aliph.),	1618	(C=N).	1H-NMR	(DMSO-d6):	ppm	4.8	[s,	2H,	CH2],	5.9	[s,	2H,	
O-CH2-O],	 6.8-8.6	 [m,	 12H,	 Ar-H],	 10.2	 [s,	 1H,	 NH,	 exchangeable	 with	 D2O].	 13C-NMR	
(DMSO-d6):	 ppm	 44.5,	 101.3,	 108.4,	 108.5,	 113.4,	 120.9,	 124.2,	 127.2	 (2),	 129.1	 (2),	
132.4	 (2),	132.9,	133.3,	134.8	 (2),	146.5,	146.7,	147.7,	158.4,	163.4.	MS	m/z	 (%):	 	355	
(M+)	 (22.15),	233	 (100).	Anal.	Calcd.	 For	C22H17N3O2	 (355):	C,	74.35;	H,	4.82;	N,	11.82.	
Found:	C,	74.08;	H,	4.59;	N,	12.10.	
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2-	Phenyl-N-(5,6,7,8-tetrahydronaphthalen-1-yl)quinazolin-4-amine	(5).		
White	solid;	yield,	77%;	m.p.	192-3	oC.	IR	(KBr,	cm-1):	3412	(NH),	3068	(CH	arom.),	2922,	
2782	(CH	aliph.),	1609	(C=N).	1H-NMR	(DMSO-d6):	ppm	1.6-2.8	[m,	8H,	4CH2	Cyclo],	7.0-
9.0	[m,	12H,	Ar-H],	11.4	[s,	1H,	NH,	exchangeable	with	D2O].	13C-NMR	(DMSO-d6):	ppm	
22.6	(2),	25.0,	29.6,	113.0	(2),	125.1,	125.3,	125.8,	128.0,	128.7	(2),	129.1	(2),	129.3	(2),	
133.1,	134.1,	135.7,	135.8,	138.4,	157.7,	160.1,	163.4.	MS	m/z	(%):		351	(M+)	(7.13),	294	
(100).	Anal.	 Calcd.	 For	C24H21N3	 (351):	C,	 82.02;	H,	 6.02;	N,	11.96.	 Found:	C,	 82.34;	H,	
5.81;	N,	12.21.	
	
N-(Naphthalen-1-yl)-phenylquinazolin-4-amine	(6).		
White	solid;	yield,	79%;	m.p.	143-5	oC.	IR	(KBr,	cm-1):	3401	(NH),	3100	(CH	arom.),	2981,	
2780	(CH	aliph.),	1629	(C=N).	 1H-NMR	(DMSO-d6):	ppm	7.1-8.9	[m,	16H,	Ar-H],	11.2	[s,	
1H,	NH,	exchangeable	with	D2O].	13C-NMR	(DMSO-d6):	ppm	113.7,	119.4,	122.4,	122.8,	
124.1,	 124.7,	 125.2,	 126.0,	 126.2,	 126.5	 (2),	 127.3,	 127.4,	 128.2,	 128.7,	 129.0,	 130.0,	
131.8,	133.1,	134.1,	135.0,	158.6,	160.8,	163.4.	MS	m/z	(%):		347	(M+)	(11.23),	269	(100).	
Anal.	Calcd.	For	C24H17N3	(347):	C,	82.97;	H,	4.93;	N,	12.10.	Found:	C,	82.64;	H,	5.21;	N,	
11.86.	
	
2-Phenyl-N-(quinolin-2-yl)quinazolin-4-amine	(7).		
White	solid;	yield,	69%;	m.p.	191-2	oC.	IR	(KBr,	cm-1):	3411	(NH),	3024	(CH	arom.),	2977,	
2839,	2780	(CH	aliph.),	1635	(C=N).	1H-NMR	(DMSO-d6):	ppm	7.1-8.9	[m,	15H,	Ar-H],	9.1	
[s,	 1H,	 NH,	 exchangeable	 with	 D2O].	 13C-NMR	 (DMSO-d6):	 ppm	 112.6,	 116.7,	 117.2,	
123.1,	126.6	(2),	127.7,	127.8	(2),	128.0	(2),	129.2	(2),	129.3,	129.5,	129.8,	133.1,	135.4,	
138.4	(2),	157.1,	161.7,	164.8.	MS	m/z	(%):		348	(M+)	(24.07),	209	(100).	Anal.	Calcd.	For	
C23H16N4	(348):	C,	79.29;	H,	4.63;	N,	16.08.	Found:	C,	79.55;	H,	4.38;	N,	16.36.	
	
2-Phenyl-N-(quinolin-3-yl)quinazolin-4-amine	(8).		
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White	solid;	yield,	91%;	m.p.	281-2	oC.	IR	(KBr,	cm-1):	3321	(NH),	3059	(CH	arom.),	1624	
(C=N).	 1H-NMR	 (DMSO-d6):	 ppm	7.4-9.3	 [m,	 15H,	Ar-H],	 10.3	 [s,	 1H,	NH	exchangeable	
with	D2O].	13C-NMR	(DMSO-d6):	ppm	114.4,	121.4,	124.8,	125.6,	126.3,	126.5,	127.0	(2),	
127.9,	 128.1,	 128.4,	 128.9	 (2),	 129.1,	 130.2,	 131.8,	 132.2,	 133.9,	 138.2,	 144.7,	 149.2,	
162.7,	163.2.	MS	m/z	(%):		348	(M+)	(39.41),	270	(100).	Anal.	Calcd.	For	C23H16N4	(348):	
C,	79.29;	H,	4.63;	N,	16.08.	Found:	C,	79.56;	H,	4.32;	N,	16.29.	
N-(2-Methylquinolin-4-yl)-2-phenylquinazolin-4-amine	(9).		
White	solid;	yield,	88%;	m.p.	236-8	oC.	IR	(KBr,	cm-1):	3433	(NH),	3023	(CH	arom.),	2976,	
2839,	2779	(CH	aliph.),	1609	(C=N).	1H-NMR	(DMSO-d6):	ppm	2.5	[s,	3H,	CH3],	7.5-8.0	[m,	
14H,	 Ar-H],	 12.5	 [s,	 1H,	 NH	 exchangeable	 with	 D2O].	 13C-NMR	 (DMSO-d6):	 ppm	 19.8,	
102.0,	115.5,	119.7,	121.4,	124.2,	126.1,	126.4	(2),	127.0,	127.9,	128.2,	128.9	(2),	129.7,	
131.8,	133.1,	133.9,	149.1,	152.8,	153.2,	158.1,	162.7	(2).	MS	m/z	(%):		362(M+)	(24.09),	
347	(100).	Anal.	Calcd.	For	C24H18N4	(362):	C,	79.54;	H,	5.01;	N,	15.46.	Found:	C,	79.22;	H,	
4.87;	N,	15.18.	
	
4-Methyl-7-(2-phenylquinazolin-4-ylamino)-2H-chromen-2-one	(10).		
Orange	 solid;	 yield,	 78%;	m.p.	 279-80	 oC.	 IR	 (KBr,	 cm-1):	 3356	 (NH),	 3062	 (CH	 arom.),	
2946,	2869,	2765	(CH	aliph.),	1699	(C=O),	1618	(C=N).	1H-NMR	(DMSO-d6):	ppm	2.4	[s,	
3H,	CH3],	6.2	[s,	1H,	CH	Chromene],	7.5-8.6	[m,	12H,	Ar-H],	10.1	[s,	1H,	NH	exchangeable	
with	D2O].	13C-NMR	(DMSO-d6):	ppm	18.5,	108.1	(2),	112.7,	114.5,	115.3,	123.5,	125.9,	
126.7	(2),	128.3,	128.7,	129.0	(2),	130.9,	134.0,	138.6,	143.3,	151.0,	153.6,	154.0,	158.1,	
159.3,	160.6.	MS	m/z	(%):		379	(M+)	(9.64),	294	(100).	Anal.	Calcd.	For	C24H17N3O2	(379):	
C,	75.97;	H,	4.52;	N,	11.08.	Found:	C,	75.61;	H,	4.87;	N,	10.78.	
	
7-(2-Phenylquinazolin-4-ylamino)-4-(trifluoromethyl)-2H-chromen-2-one	(11).		
Yellow	solid;	yield,	72%;	m.p.	255-7	oC.	IR	(KBr,	cm-1):	3355	(NH),	3058	(CH	arom.),	1697	
(C=O),	1617	(C=N).	1H-NMR	(DMSO-d6):	ppm	6.2	[s,	1H,	CH	Chromene],	7.2-8.6	[m,	12H,	
Ar-H],	10.1	[s,	1H,	NH	exchangeable	with	D2O].	13C-NMR	(DMSO-d6):	ppm	106.3,	108.1,	
112.6,	112.9,	114.5,	121.4,	123.5,	124.7,	125.9	(2),	126.5,	127.0,	128.3	(2),	129.0,	130.9,	
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133.1,	143.5,	149.2,	154.0,	158.1,	160.6,	160.7,	162.6.	MS	m/z	(%):		433	(M+)	(1.98),	355	
(100).	Anal.	Calcd.	For	C24H14F3N3O2	(433):	C,	66.51;	H,	3.26;	N,	9.70.	Found:	C,	66.21;	H,	
3.54;	N,	9.98.	
	
	
	
N-(4-Morpholinophenyl)-2-phenylquinazolin-4-amine	(12).		
White	solid;	yield,	86%;	m.p.	228-9	oC.	IR	(KBr,	cm-1):	3334	(NH),	3059	(CH	arom.),	2977,	
2891,	 2860	 (CH	 aliph.),	 1617	 (C=N).	 1H-NMR	 (DMSO-d6):	 ppm	 2.8-3.7	 [m,	 8H,	 4CH2	
Cyclo],	7.0-8.5	[m,	13H,	Ar-H],	9.9	[s,	1H,	NH	exchangeable	with	D2O].	13C-NMR	(DMSO-
d6):	ppm	49.2	(2),	66.6	(2),	114.5	(2),	115.4,	123.4	(2),	126.1,	128.3	(2),	128.5	(2),	128.8	
(2),	 130.6,	 131.6,	 133.4	 (2),	 138.9,	 148.0,	 159.6,	 162.7.	MS	m/z	 (%):	 382	 (M+)	 (12.23),	
295	(100).	Anal.	Calcd.	For	C24H22N4O	(382):	C,	75.37;	H,	5.80;	N,	14.65.	Found:	C,	75.04;	
H,	5.44;	N,	14.31.	
	
Biological	evaluation	
Hepa1c1c7	murine	hepatoma	cells	were	maintained	 in	a	humidified	atmosphere	at	37	
oC,	5%	CO2	 in	α-MEM	supplemented	with	10%	(v/v)	 fetal	bovine	serum.	Cells	 (104	per	
well)	 were	 grown	 for	 24	 h	 in	 96-well	 plates.	 For	 evaluation	 of	 the	 potential	 NQO1	
inducer	activity	of	the	new	2-phenylquiazolin-4-amines	2-12,	the	medium	was	replaced	
with	inducer-containing	fresh	medium,	and	the	cells	were	further	grown	for	48	h.	There	
were	eight	replicates	of	each	treatment	of	eight	different	concentrations	of	inducers.	All	
compounds	were	dissolved	in	DMSO,	and	diluted	in	the	cell	culture	medium	at	a	ratio	of	
1:1000	prior	 to	 screening	experiments.	The	 final	 solvent	concentration	 in	 the	medium	
was	 0.1%	 (v/v)	 in	 all	 wells.	 At	 the	 end	 of	 the	 treatment	 period,	 cell	 lysates	 were	
prepared	 in	 digitonin	 and	 the	 specific	 activity	 of	 NQO1	 was	 determined	 using	
menadione	as	a	substrate	as	previously	described22.	The	Concentration	which	Doubles	
the	 specific	 activity	 of	 NQO1	 (CD	 value)	 was	 used	 as	 a	 measure	 of	 inducer	 potency.	
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Mean	values	for	the	eight	replicate	wells	are	shown	for	each	data	point.	The	standard	
deviation	for	each	data	point	was	within	5%	of	the	value.	
	
Molecular	modeling	study	
The	3D	molecular	models	of	 the	newly	 synthesized	phenylquinazolinamine	derivatives	
were	 built	 according	 to	 the	 default	 parameters,	with	 the	MOE	 software	 suite	 version	
10.2009.	 Geometry	 optimization	 as	 well	 as	 a	 systematic	 conformational	 search	 was	
carried	 out	 to	 an	 RMS	 gradient	 of	 0.01	 Å	 employing	 the	 ConfSearch	 module	
implemented	 in	 MOE.	 All	 computations	 were	 performed	 with	 the	 Merck	 Force	 Field	
(MMFF94s).	 To	 evaluate	 our	 compounds’	 ability	 to	 access	 and	 block	 the	Nrf2-binding	
site	 of	 Keap1,	 a	 molecular	 docking	 study	 was	 performed	 using	 the	 crystallographic	
structure	of	the	Kelch	domain	of	Keap1	obtained	from	the	Protein	Data	Bank	(PDB	ID:	
4IQK).	The	protein	target	was	prepared	for	docking	by	addition	of	the	missing	hydrogens	
and	 calculating	 the	 partial	 charges.	 Internal	 validation	 was	 performed	 to	 the	 native	
ligand	followed	by	docking	of	the	compounds	where	the	target	protein	was	kept	rigid,	
while	 ligands	were	allowed	to	rotate	 to	accommodate	 freely	 inside	the	protein	cavity.	
Following	 multiple	 separate	 docking	 simulations	 using	 default	 parameters,	 the	 best	
conformations	were	chosen	based	on	the	combination	of	S	score	data,	E	conformation	
and	appropriate	fitting	with	the	relevant	amino	acids	in	the	binding	pocket.	
	
Results	and	discussion	
Chemistry	
The	aim	of	this	work	was	to	design	and	synthesize	a	novel	series	of	quinazolines	bearing	
biologically	 active	 heterocyclic	 moieties	 to	 evaluate	 and	 explore	 their	 NQO1	 inducer	
activity.	Therefore,	4-aminoquinazoline	derivatives	2-12	were	synthesized	starting	from	
4-chloro-2-phenylquinazoline	 (1)	 as	 depicted	 in	 Scheme	 1.	 Compounds	 2-12	 were	
obtained	 in	good	yield	via	reaction	of	1	with	different	amines,	namely	5-aminoindane,	
3,4-(methylenedioxy)aniline,	 pipronylamine,	 5,6,7,8-tetrahydro-1-naphthylamine,	 1-
naphthylamine,	 2-aminoquinoline,	 3-aminoquinoline,	 4-aminoquinaldine,	 7-amino-4-
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methyl-coumarin,	7-amino-4-(trifluoromethyl) coumarin,	and	4-morpholinoaniline	in	dry	
dimethyl	 formamide	 (Scheme	 1).	 All	 the	 synthesized	 compounds	were	 established	 on	
basis	of	elemental	analyses,	IR,	1H-NMR,	13C-NMR	and	mass	spectral	data.	IR	spectra	of	
compounds	2-12	 revealed	 the	 presence	 of	 the	 characteristic	 bands	 for	 the	 NH	 group	
ranging	 from	3441	 to	3238	cm-1,	 the	aromatic	CH	around	3100	 to	3023	cm-1,	 the	C=N	
group	from	1635	to	1609	cm-1.	1H-NMR	spectra	of	compounds	2-12	exhibited	signals	at	
δ	12.5-9.1	ppm	attributed	to	the	NH	group.	1H-NMR	spectrum	of	compound	2	revealed	
a	 multiplet	 at	 δ	 1.9-2.8	 ppm	 assigned	 to	 the	 3CH2	 groups.	 13C-NMR	 spectrum	 of	
compound	2	exhibited	signals	at	δ	25.6,	32.9,	32.9	ppm	for	3CH2	groups.			Also,	1H-NMR	
spectrum	of	compound	3	showed	a	signal	at	δ	6.2	ppm	for	the	O-CH2-O	group	while	its	
13C-NMR	spectrum	revealed	a	singlet	at	δ	101.4	ppm	for	the	same	group.	 	 In	addition,	
1H-NMR	 spectrum	 of	 compound	5	 gave	 a	multiplet	 at	 δ	 1.6-2.8	 ppm	 assigned	 to	 the	
4CH2	groups.	13C-NMR	spectrum	of	compound	5	revealed	signals	at	22.6,	22.6,	25.0	and	
29.6	 ppm	 attributed	 to	 the	 aforementioned	 groups.	 On	 the	 other	 hand,	 1H-NMR	
spectrum	of	 compound	10	 revealed	 the	 presence	 of	 a	 singlet	 at	 2.4	 ppm	 for	 the	 CH3	
group	and	6.2	ppm	for	the	CH	of	chromene.	13C-NMR	spectrum	of	compound	10	showed	
a	singlet	at	18.5	ppm	attributed	to	the	CH3	group,	112.7	ppm	due	to	the	chromene	CH	
and	 159.3	 ppm	 for	 the	 C=O	 group.	 	 IR	 spectrum	 of	 11	 showed	 the	 presence	 of	 a	
characteristic	 band	 at	 1697	 cm-1	 for	 the	 C=O.	 1H-NMR	 spectrum	 of	 compound	 11	
revealed	 the	 presence	 of	 a	 singlet	 at	 6.2	 ppm	 for	 the	 chromene	 CH	 group.	 13C-NMR	
spectrum	 of	 compound	 11	 showed	 signals	 at	 112.6,	 123.5	 and	 160.7	 ppm	 for	 CH	
chromene,	 CF3	 and	 C=O	 groups,	 respectively.	 1H-NMR	 spectrum	 of	 compound	 12	
revealed	 the	presence	of	 a	multiplet	 at	 2.8-3.7	 ppm	 for	 the	morpholino	 4CH2	 groups.	
13C-NMR	spectrum	of	compound	12	showed	signals	at	49.2,	66.6	ppm	corresponding	to	
the	CH2-N-CH2	and	the	CH2-O-CH2	morpholino	4CH2	groups,	respectively.	
	
Biological	evaluation	
NQO1	 inducer	 activity	 assessment	 represented	 in	 Figure	 1	 and	 Table	 1	 revealed	 that	
while	 the	 dihydroindenyl	 derivative	 2	 was	 devoid	 of	 NQO1	 inducer	 activity,	 its	 dioxo	
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bioisostere	compound	3	displayed	relatively	high	potency	 (extrapolated	CD	=	0.5	μM),	
however,	 this	was	of	 low	magnitude	and	 lacked	dose-dependency.	 In	addition,	 the	N-
benzo[d][1,3]dioxol-5-yl	derivative	3	was	cytostatic/cytotoxic	at	concentrations	greater	
than	12.5	μM	as	evidenced	by	the	more	than	50%	lower	levels	of	protein	content	in	the	
lysates	of	treated	cells.	On	the	other	hand,	 introduction	of	methylene	spacer	between	
the	4-amino	group	of	 the	quinazoline	and	the	benzo[d][1,3]dioxole	ring	gave	a	weakly	
active	derivative	4	where	a	CD	value	wasn’t	reached.	Regarding	the	tetrahydronaphthyl	
derivative	5	 and	 the	morpholinophenyl	 compound	12,	 both	displayed	weak	activity	 (a	
CD	value	was	not	reached),	with	no	clear	dose	dependence.	In	contrast,	the	naphth-1-yl	
derivative	 6	 compound	 showed	 a	moderate	 dose-dependent	 inducer	 activity	 (CD	 =	 1	
μM).	 Furthermore,	 the	 2-methyl-quinolin-4-yl	 analog	 9	 displayed	 a	moderate	 inducer	
potency	 (CD	 =	 4	 μM)	which	was	 dose-dependent,	 indicating	 that	 these	modifications	
were	 not	 much	 in	 favor	 of	 activity	 as	 compared	 to	 the	 naphthyl	 bioisostere	 6.	 The	
bioisosteres	7	and	8	demonstrated	a	big	difference	in	activity.	Whereas,	the	quinolin-2-
yl	 derivative	 7	 had	 the	 highest	 potency	 in	 this	 study	 (CD	 =	 0.4	 μM),	 the	 3	 positional	
isomer	8	 was	mre	 than	 twice	 less	 potent	 (CD	 =	 0.9	 μM).	 Finally,	 with	 regards	 to	 the	
bioisosteric	 pair	 10	 and	 11	 (CD	 =	 3	 and	 1.6	 μM,	 respectively)	 it	 was	 evident	 that	
replacement	of	 the	methyl	 group	with	 a	 triflouromethyl	 almost	 doubled	 the	potency.	
Although	almost	similar	in	potency,	compounds	6	(CD	=	1	μM)	and	8	(CD	=	0.9	μM)	were	
very	 different	 in	 terms	 of	 dose	 responsiveness.	 Thus,	 whereas	 induction	 was	 dose-
dependent	 for	 compound	 6,	 it	 was	 not	 for	 compound	 8.	 Compound	 7	 was	 the	most	
potent	 inducer	 (CD	 =	 0.4	 μM),	 and	 importantly,	 had	 the	 most	 favorable	 inducer	
properties	within	this	series.	
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Figure	1:	Concentration	dependence	of	NQO1	inducer	activity	of	quinazoline	derivatives.	
	
	
Table	1:	NQO1	inducer	activity	and	CD	values	of	the	test	compounds.	
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Concentration	
	(uM)	
Compound	#	
2	 3	 4	 5	 6	 7	 8	 9	 10	 11	 12	
0.09765	 NR*	 NR	 NR	 NR	 NR	 1.34	 NR	 NR	 NR	 NR	 NR	
0.1953	 NR	 NR	 NR	 NR	 NR	 1.49	 NR	 NR	 NR	 NR	 NR	
0.3906	 NR	 NR	 1.27	 NR	 NR	 1.81	 NR	 NR	 NR	 NR	 NR	
0.781	 1.16	 2.31	 1.41	 1.19	 1.82	 2.43	 1.93	 1.34	 1.50	 1.83	 1.64	
	
	
12	
	
*NR	=	not	recorded	
**	CD	data	presented	are	the	averages	of	3	independent	experiments,	each	with	8	replicates	wells	of	
cells,	and	SD	(standard	deviation)	for	each	data	point	was	within	5%	of	the	value.	
	
	
1.563	 1.02	 2.42	 1.53	 1.33	 2.24	 3.33	 2.36	 1.5	 1.77	 2.03	 1.66	
3.125	 0.93	 2.44	 1.66	 1.44	 2.98	 4.3	 2.39	 1.81	 2.09	 2.08	 1.45	
6.25	 0.88	 2.41	 1.71	 1.5	 3.71	 5.14	 2.2	 2.3	 2.21	 2.04	 1.53	
12.5	 0.87	 2.2	 1.78	 1.55	 4.34	 5.5	 2.12	 2.92	 2.37	 2.02	 1.47	
25	 0.81	 1.88	 1.77	 1.71	 4.69	 NR	 1.76	 3.57	 2.36	 NR	 NR	
50	 0.83	 1.7	 1.56	 1.82	 4.69	 NR	 NR	 4.61	 NR	 NR	 NR	
100	 0.8	 1.5	 NR	 1.87	 3.65	 NR	 NR	 4.82	 NR	 NR	 NR	
CD**	 NR	 0.5	 NR	 NR	 1	 0.4	 0.9	 4	 3	 1.6	 NR	
	
	
13	
	
Scheme	1:	Synthesis	of	quinazoline	derivatives	2-12.
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Molecular	modeling	study	
Keap1	 is	 known	 to	 bind	 to	 Nrf2	 promoting	 its	 degradation,	 resulting	 in	 low	 levels	 of	
cytoprotective	 gene	 products.	 Various	 small	 molecule	 compounds	 were	 reported	 to	
bind	 to	 the	 Keap1	 Kelch	 domain	 and	 antagonize	 its	 activity23,24,25.	 For	 assessing	 	 the	
newly		synthesized	compounds’	ability	to	access	and	block	the	Kelch	domain	of	Keap1,	a	
molecular	docking	 study	was	performed	using	 the	Keap1	 crystal	 coordinates	obtained	
from	the	Protein	Data	Bank	(PDB	ID:	4IQK).	The	main	interactions	observed	between	the	
validated	native	ligand	and	the	protein	target	were	found	to	be	arene-cation	interaction	
with	Arg415,	arene-arene	 interaction	with	Tyr525	and	3	hydrogen	bonds	with	Ser602,	
Ser508	and	Ser555	with	 S	 =	 -13.306	Kcal/mol	 and	 rmsd	0.6635	Kcal/mol/Å	 (Figure	2).	
Upon	docking	of	the	synthesized	compounds,	they	all	showed	an	arene–cation	binding	
interaction	with	Arg415	via	their	aromatic	rings.	Compound	11	(S=	-10.913	Kcal/mol)	has	
adopted	 a	 conformation	 allowing	 the	 presence	 of	 3	 arene–cation	 interactions	 with	
Arg415	and	multiple	rings	of	the	ligand	(Figures	3	and	4).		
	
	
Figure	2:	Interactions	of	the	native	ligand	with	the	Kelch	domain	of	Keap1	(PDB	ID:	41QK).	
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Figure	3:	Interactions	of	compound	11	with	the	Kelch	domain	of	Keap1	(PDB	ID:	41QK).	
	
	
Figure	4:	Overlap	of	Compound	11	(maroon)	over	native	ligand	(yellow)	(PDB	ID:	41QK)	
	
Finally,	compound	7	that	showed	the	most	potent	NQO1	inducer	activity	(CD	=	0.4	µM)	
was	 the	 only	 compound	 that	 showed	 3	 arene-cation	 interactions	 with	 Arg415	 and	 2	
arene-arene	 interactions	with	 Tyr525	 indicating	 a	 possible	 correlation	 between	 those	
multiple	interactions	and	the	noted	high	potency	(S	=	-10.7652	Kcal/mol)	(Figures	5	and	
6).		
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Figure	5:	Interaction	of	compound	7	with	the	Kelch	domain	of	Keap1	(PDB	ID:	41QK)	
	
	
Figure	6:	Overlap	of	Compound	7	(magneta)	over	native	ligand	(cyan)	(PDB	ID:	41QK)	
	
One	limitation	of	our	study	is	the	lack	of	a	well-established	biological	assay	for	assessing	
the	 ability	 of	 small	 molecules	 to	 disrupt	 the	 Keap1-Nrf2	 protein-protein	 interactions.	
Therefore,	 although	 the	molecular	 docking	 study	 suggests	 that	 these	 compounds	 can	
potentially	 bind	 to	 Keap1	 and	 disrupt	 its	 interaction	 with	 Nrf2,	 further	 experimental	
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evidence	is	required	to	confirm	this	possibility.	Regardless	of	the	precise	mode	of	action	
in	activating	Nrf2,	 the	 inducer	potency	of	 compound	7	 in	upregulating	NQO1	strongly	
suggests	 that	 this	 compound	 could	 be	 used	 as	 a	 lead	 for	 further	 optimization	 of	 the	
quinazoline	scaffold.	
	
Conclusion	
In	 conclusion,	 this	 study	presents	 the	 synthesis	of	N-substituted	2-phenylquinazolin-4-
amine	 based	 derivatives	 2-12	 as	 cytoprotective	 NQO1	 inducers.	 	 The	 most	 potent	
inducer	 in	this	study	was	the	analogue	7	which	caused	a	dose-dependent	 induction	of	
NQO1	with	a	CD	value	of	0.4	μM.	In	silico	evaluation	of	these	derivatives	as	Keap1-Nrf2	
protein-protein	 interaction	 inhibitors	 was	 performed	 using	 molecular	 docking	
techniques	employing	MOE	software	version	10.2009.	Derivatives	were	found	to	bind	to	
key	amino	acids	 in	 the	binding	 site	with	a	network	or	arene-arene	and	arene-cationic	
interactions.	These	molecules	represent	promising	quinazoline	scaffold-based	leads	for	
further	 optimization	 as	 cytoprotective	 agents	 and	 for	 future	 investigations	 into	 other	
plausible	modes	of	action.	
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